PBM helmet device
Phase 2- Indications
- Alzheimer's disease
Company intelligence / Profile preview
REGEnLIFE
Paris, Île-de-France, Franceregenlifeantiaging.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
REGEnLIFE has developed a non-invasive medical device that uses tri-photonic stimulation to target the brain and gut for reducing neuroinflammation. The company presented the design of its Light4life clinical trial at CTAD, evaluating cognitive impacts in over 100 subjects with Alzheimer’s disease. The RGn600 device represents their lead program. As of late 2022–2023, they are finalizing development with recent Series A funding. No published pivotal results yet.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Device (specifically photobiomodulation device)Non-pharmacological therapy (light-based therapy)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
None publicly disclosed as of June 2025.
Beyond the preview
Go deeper on REGEnLIFE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGEnLIFE.